Gerd Asal

Sales of its Gardasil vaccine, for preventing a sexually transmitted, cancer-causing virus, climbed 26 percent, to $1.32.

Higher demand in China, along with higher prices in the United States, boosted third-quarter sales of Gardasil, the company’s.

Higher demand in China, along with higher prices in the United States, boosted third-quarter sales of Gardasil, the company’s vaccine to prevent cancer caused by human papillomavirus. Gardasil.

Pfizer rose 2.8% after it raised its forecast for the year. Merck gained 3.8% after reporting big jumps in sales for its top.

Pfizer rose 2.5% after it raised its forecast for the year. Merck gained 3.5% after reporting big jumps in sales for its top two blockbuster drugs, cancer drug Keytruda and vaccine Gardasil. General.

SILVER SPRING, Md., Oct. 5, 2018 /PRNewswire/ — The U.S. Food and Drug Administration today approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine,

Sales of its Gardasil vaccine, for preventing a sexually transmitted, cancer-causing virus, climbed 26%, to $1.32 billion. The maker of Januvia Type 2 diabetes pills and vaccines on Tuesday reported.

But Keytruda wasn’t the only great story for Merck in the quarter. Sales of human papillomavirus (HPV) vaccine Gardasil.

Sales of its Gardasil vaccine, for preventing a sexually transmitted, cancer-causing virus, climbed 26%, to $1.32 billion. Pfizer’s third-quarter profit nearly doubled after it booked a $8.1 billion.

Pfizer shares rose 3% after it raised its forecast for the year. Merck stock gained 3.4% after reporting big jumps in sales.

Pfizer rose 3% after it raised its forecast for the year. Merck gained 4.2% after reporting big jumps in sales for its top.

"However, Merck also saw fantastic growth from its Gardasil franchise which saw revenues rise 26% to over $1.3 billion." Like.

Solid third-quarter results from pharmaceutical giant Merck drove the stock 4.3% higher on Tuesday. Both revenue and earnings.

The quarter were dominated again by advanced cancer drug Keytruda, with sales soaring 62% to $3.07 billion, more than a.

Meanwhile, the company’s big-selling HPV shot, Gardasil, continued to gain steam, and executives see "significant" opportunity for growth ahead for the vaccine. In the second quarter, Gardasil sales.

Merck gained 1.8% after reporting big jumps in sales for its top two blockbuster drugs, cancer drug Keytruda and vaccine.

Pfizer rose 2.5% after it raised its forecast for the year. Merck gained 3.5% after reporting big jumps in sales for its top two blockbuster drugs, cancer drug Keytruda and vaccine Gardasil. General.

Sales of its Gardasil vaccine, for preventing a sexually transmitted, cancer-causing virus, climbed 26%, to $1.32 billion.

Pfizer rose 2.8% after it raised its forecast for the year. Merck gained 2.3% after reporting big jumps in sales for its top.

[embedyt]//www.youtube.com/embed/[/embedyt]




No Comments


You can leave the first : )



Leave a Reply

Your email address will not be published. Required fields are marked *